Search

Search Constraints

You searched for: Author/Creator Leone, Peter

Search Results

1. 75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500, 000 c/mL: 48-Week Subgroup Analysis of the STAT Study. (4th December 2021)

2. 900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study). (4th December 2021)

3. 900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study). (4th December 2021)

4. Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo. (4th October 2017)

5. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial . (25th January 2022)